New Research Reveals Why GLP-1 Results Vary So Wildly From Person to Person
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated July 2026
New Research Reveals Why GLP-1 Results Vary So Wildly From Person to Person
A freshly published systematic review and meta-analysis just landed on PubMed — and it puts a name to something millions of GLP-1 users have noticed but nobody could fully explain: why does your coworker lose 50 pounds on Ozempic while you lose 12?
The answer isn't willpower. It isn't cheating on your diet. It's what researchers call heterogeneity of treatment effects — and a new analysis suggests this variation is bigger, and more predictable, than previously understood.
Important: I'm not a doctor. Everything shared here is based on published research. Talk to your physician before making any changes to your health regimen.
The Bottom Line
- A new systematic review confirms that GLP-1 drugs produce dramatically different results depending on who's taking them — this is now a formal, well-documented research finding, not just anecdote.
- Factors like baseline body weight, diabetes status, age, and sex appear to influence how much weight a person loses on these drugs.
- People with higher starting weight and no diabetes tend to see the largest percentage drops — but that's an average, not a guarantee.
- Results not typical is more than a legal disclaimer here — the range of outcomes in studies is genuinely wide, and some people are non-responders.
- Actionable takeaway: If you've been on a GLP-1 drug for 12+ weeks and seen minimal results, this research supports having a serious conversation with your doctor about switching drugs, adjusting dose, or investigating underlying factors — not just waiting it out.
The Study Everyone in This Space Should Know About
The paper is titled "Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis" and it's indexed on PubMed.
Here's the short version: researchers pulled together data across multiple GLP-1 trials and asked a simple but underexplored question — is the average weight loss number we see in headlines actually what most people experience?
The answer is a pretty clear no.
The "average" figure gets reported in every press release and news article. But averages flatten the story. When you look at the full distribution of results — who lost a lot, who lost a little, who lost almost nothing — you get a much more complicated picture.
That's what this review mapped out. And it matters enormously for how you interpret your own experience on these drugs.
What "Heterogeneity of Treatment Effects" Actually Means (In Plain English)
Forget the academic phrase for a second.
Imagine 100 people all start semaglutide on the same day, at the same dose, for the same amount of time. The headline result might say "participants lost an average of 15% body weight." But inside that average, you might have:
- 20 people who lost 25% or more
- 50 people who lost 10–20%
- 20 people who lost less than 10%
- 10 people who barely lost anything at all
That spread — from excellent responders to non-responders — is what heterogeneity of treatment effects describes.
The new review found this spread is not random. Certain characteristics make a person more or less likely to be in that top group. And that's actually useful information.
Who Tends to Respond Best to GLP-1 Drugs?
Based on what the research has found across multiple GLP-1 trials, a few patterns stand out.
Higher baseline body weight is one of the clearer predictors. People who start with more weight to lose tend to show larger absolute drops — though their percentage losses can still vary. This makes some physiological sense: the drug's appetite-suppressing mechanism has more room to work when someone is significantly above their set point.
People without type 2 diabetes have consistently shown stronger weight loss responses in clinical data. In major semaglutide trials, participants without diabetes lost more weight than those managing diabetes simultaneously. The likely reason: insulin resistance and metabolic disruption in diabetes can partially blunt the drug's weight-loss signal.
Sex and age also appear to play a role, though the data here is messier. Some analyses suggest women may lose slightly more weight on GLP-1s as a percentage, while older adults may respond more slowly. Neither of these is a firm rule.
What you eat while on the drug matters more than people realize. A 2026 systematic review of nutritional management in GLP-1 users found that dietary strategy significantly influenced outcomes among people on these medications. The drug reduces appetite — but what you eat with that reduced appetite shapes results in a meaningful way.
The Non-Responder Problem Nobody Talks About
Here's the part that gets glossed over in most GLP-1 coverage.
A real portion of people don't respond well. Not because they're doing something wrong. Not because they're secretly eating more than they say. Their biology just doesn't play ball with the drug in the same way.
This isn't a small edge case. Across GLP-1 trials, the range of weight loss responses is wide enough that researchers specifically designed this new meta-analysis to quantify it.
If you're a non-responder or a weak responder, continuing the same protocol for another 6 months isn't likely to change the curve. The data supports reassessment — whether that's trying a dual agonist like tirzepatide (which targets both GIP and GLP-1 receptors and has shown stronger average weight loss in head-to-head data), adjusting lifestyle inputs, or investigating other metabolic factors.
A 2026 analysis comparing tirzepatide and semaglutide found meaningful differences in how many patients hit key metabolic targets — which reinforces that drug choice itself is a variable worth revisiting, not just dose.
The Muscle Loss Factor: A Complication in the Data
Any honest look at GLP-1 weight loss outcomes in 2026 has to address the lean mass question.
A population-based observational study published in Clinical Nutrition found that some of the weight lost on GLP-1 drugs is lean body mass — muscle — not just fat. This is a known issue with rapid caloric restriction in general, but it complicates the "more weight lost = better outcome" interpretation.
Why does this matter for the heterogeneity discussion? Because if two people each lost 15% of their body weight on semaglutide, but one lost mostly fat and the other lost a mix of fat and muscle, those are genuinely different outcomes for long-term health — even though the scale says the same thing.
Real-world data published in Diabetes, Metabolic Syndrome and Obesity found that oral nutritional supplements helped GLP-1 users preserve more lean mass during weight loss. Protein intake in particular appears to be a key lever. If you're on a GLP-1 drug, what you're eating during the caloric deficit isn't just about maximizing weight loss — it's about what kind of weight you're losing.
What the Average Number in Headlines Is Actually Telling You
When you see "semaglutide users lost 15% of body weight on average," here's what that number does and doesn't mean.
It does mean: Across a large group, the middle of the response distribution landed around 15%. This is real and significant compared to placebo.
It does not mean: You will lose 15%. Or that 15% is even close to what most individuals in the trial actually lost. The average is a mathematical center of a wide spread.
It definitely does not mean: That if you're losing less than 15%, something is wrong with you or your protocol. You might simply be in a part of the distribution that doesn't respond as strongly — and there are now data-backed reasons that can explain why.
This is exactly why the new heterogeneity meta-analysis matters. It shifts the conversation from "does this drug work?" — which we already know the answer to — toward "does this drug work for me, and what predicts that?"
What's Coming Next: Precision Prescribing for GLP-1 Drugs
This is the practical frontier the research is pointing toward.
Right now, most GLP-1 prescribing is somewhat trial-and-error. You start a drug, you wait, you see how you respond. If response is weak, you might increase dose. If still weak, you might try a different drug.
What the heterogeneity research suggests is that we should eventually be able to — and need to — get smarter about predicting response before someone spends months on a drug that isn't going to work well for them.
Factors being studied as potential predictors include genetic markers, gut microbiome composition, baseline insulin sensitivity, and hormonal profile. None of these are ready for routine clinical use as prescribing guides yet. But the research direction is clear.
For now, the most actionable version of this insight is: if you're not responding well after an adequate trial period, that's a data point worth acting on — not ignoring.
FAQ
Why do some people lose more weight on Ozempic than others?
Research now formally confirms that GLP-1 drugs produce widely different results from person to person. Factors including starting weight, diabetes status, age, sex, diet quality, and possibly genetics all appear to influence how much weight someone loses. This is called heterogeneity of treatment effects, and a 2025/2026 systematic review specifically studied this variation in GLP-1 trials.
Does having diabetes make GLP-1 drugs less effective for weight loss?
In clinical trial data, people without type 2 diabetes have generally shown larger weight loss responses to GLP-1 drugs compared to those managing diabetes at the same time. This doesn't mean the drugs don't help people with diabetes — they clearly do, including for blood sugar management — but the weight loss magnitude tends to be somewhat smaller on average.
How long should I try a GLP-1 drug before deciding it's not working?
Most clinical protocols evaluate response at 12–16 weeks at an effective dose. If you've reached a therapeutic dose and maintained it for that period with minimal weight loss, current research supports discussing a change in approach with your doctor — whether that's a different medication, dose adjustment, or investigating other factors. Don't just wait indefinitely.
Can what I eat change how well GLP-1 drugs work?
Yes — meaningfully. A 2026 systematic review found dietary strategy significantly influenced outcomes among GLP-1 users. Higher protein intake, in particular, appears to help preserve muscle mass during weight loss on these drugs, which matters for long-term metabolic health beyond the number on the scale.
Is tirzepatide better than semaglutide if I'm a weak responder to GLP-1s?
Tirzepatide targets two receptors (GIP and GLP-1) versus semaglutide's one. Head-to-head data shows tirzepatide produces stronger average weight loss. Whether switching would benefit a specific weak responder depends on individual factors — this is a conversation to have with your prescribing doctor, not a one-size answer.
The Takeaway: Your Results Aren't Random — But They Aren't Guaranteed Either
The new research on GLP-1 heterogeneity of treatment effects is, in a way, both reassuring and clarifying.
Reassuring because if you've had a weaker-than-expected response, there are real, documented reasons for that — it's not a personal failing.
Clarifying because it means the headline numbers you've been comparing yourself to are less meaningful than you thought. The "average" result was never really what you were chasing. Your baseline, your biology, your dietary choices, and possibly your drug selection are all variables that matter.
The practical next step: if you're currently on a GLP-1 drug, use this research as a prompt to have a more specific conversation with your doctor. Not "is this working?" but "what does my response pattern suggest about whether this particular drug at this particular dose is right for me?"
That's a more useful question. And now there's research to back it up.
Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.
Sources
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis — PubMed, 2025/2026
- Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials — Diabetes, Obesity & Metabolism, 2026
- Muscle Atrophy Associated with Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Observational Study — Clinical Nutrition, 2026
- Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence — Diabetes, Metabolic Syndrome and Obesity, 2026
- Efficacy of Tirzepatide Versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: A Post Hoc Analysis of the SURPASS-2 Trial — PubMed, 2026
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.